



HAL
open science

Dissecting autism and schizophrenia through neuroimaging genomics

Clara Moreau, Armin Raznahan, Pierre Bellec, Mallar Chakravarty, Paul
Thompson, Sebastien Jacquemont

► **To cite this version:**

Clara Moreau, Armin Raznahan, Pierre Bellec, Mallar Chakravarty, Paul Thompson, et al.. Dissecting autism and schizophrenia through neuroimaging genomics. *Brain - A Journal of Neurology*, Oxford University Press (OUP), 2021, 144 (7), pp.1943-1957. 10.1093/brain/awab096 . pasteur-03503367

HAL Id: pasteur-03503367

<https://hal-pasteur.archives-ouvertes.fr/pasteur-03503367>

Submitted on 27 Dec 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.




L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial | 4.0 International
License



Dissecting autism and schizophrenia through neuroimaging genomics

 Clara A. Moreau,^{1,2,3}  Armin Raznahan,⁴ Pierre Bellec,² Mallar Chakravarty,⁵ Paul M. Thompson^{6,†} and  Sebastien Jacquemont^{1,†}

[†]These authors contributed equally to this work.

Neuroimaging genomic studies of autism spectrum disorder and schizophrenia have mainly adopted a ‘top-down’ approach, beginning with the behavioural diagnosis, and moving down to intermediate brain phenotypes and underlying genetic factors. Advances in imaging and genomics have been successfully applied to increasingly large case-control studies. As opposed to diagnostic-first approaches, the bottom-up strategy begins at the level of molecular factors enabling the study of mechanisms related to biological risk, irrespective of diagnoses or clinical manifestations. The latter strategy has emerged from questions raised by top-down studies: why are mutations and brain phenotypes over-represented in individuals with a psychiatric diagnosis? Are they related to core symptoms of the disease or to comorbidities? Why are mutations and brain phenotypes associated with several psychiatric diagnoses? Do they impact a single dimension contributing to all diagnoses?

In this review, we aimed at summarizing imaging genomic findings in autism and schizophrenia as well as neuropsychiatric variants associated with these conditions.

Top-down studies of autism and schizophrenia identified patterns of neuroimaging alterations with small effect-sizes and an extreme polygenic architecture. Genomic variants and neuroimaging patterns are shared across diagnostic categories suggesting pleiotropic mechanisms at the molecular and brain network levels. Although the field is gaining traction; characterizing increasingly reproducible results, it is unlikely that top-down approaches alone will be able to disentangle mechanisms involved in autism or schizophrenia.

In stark contrast with top-down approaches, bottom-up studies showed that the effect-sizes of high-risk neuropsychiatric mutations are equally large for neuroimaging and behavioural traits. Low specificity has been perplexing with studies showing that broad classes of genomic variants affect a similar range of behavioural and cognitive dimensions, which may be consistent with the highly polygenic architecture of psychiatric conditions.

The surprisingly discordant effect sizes observed between genetic and diagnostic first approaches underscore the necessity to decompose the heterogeneity hindering case-control studies in idiopathic conditions. We propose a systematic investigation across a broad spectrum of neuropsychiatric variants to identify putative latent dimensions underlying idiopathic conditions. Gene expression data on temporal, spatial and cell type organization in the brain have also considerable potential for parsing the mechanisms contributing to these dimensions’ phenotypes. While large neuroimaging genomic datasets are now available in unselected populations, there is an urgent need for data on individuals with a range of psychiatric symptoms and high-risk genomic variants. Such efforts together with more standardized methods will improve mechanistically informed predictive modelling for diagnosis and clinical outcomes.

1 Sainte Justine Research Center, University of Montréal, Montréal, Québec H3T 1C5, Canada

2 Centre de Recherche de l’Institut Universitaire de Gériatrie de Montréal, Montreal, Québec H3W 1W5, Canada

3 Human Genetics and Cognitive Functions, CNRS UMR 3571, Université de Paris, Institut Pasteur, Paris, France

4 Section on Developmental Neurogenomics, Human Genetics Branch, National Institute of Mental Health Intramural Research Program, Bethesda, MD 20892, USA

5 Cerebral Imaging Centre, Douglas Hospital Mental Health University Institute, Verdun, Québec H4H 1R3, Canada

6 Imaging Genetics Center, Stevens Institute for Neuroimaging and Informatics, USC Keck School of Medicine, Marina del Rey, CA 90033, USA

Correspondence to: Sebastien Jacquemont, MD

Sainte Justine Research Center, University of Montréal, Montréal, 3175 chemin de la Côte-Sainte-Catherine Montréal, Québec H3T 1C5, Canada

E-mail: sebastien.jacquemont@umontreal.ca

Keywords: autism; schizophrenia; copy number variants; neuroimaging

Abbreviations: ADHD = attention deficit hyperactivity disorder; ASD = autism spectrum disorder; CNV = copy number variant; DMN = default mode network; OCD = obsessive-compulsive disorder; SNP = single nucleotide polymorphism

Introduction: clinical diversity in autism and schizophrenia

Evolving boundaries

The nature and definition of autism spectrum disorder (ASD) and schizophrenia have been highly debated for decades. Classifications evolved over time, merging and splitting clinical manifestations. The broadening of diagnostic criteria together with improved clinical awareness has resulted in an increase of ASD prevalence in the past decades, reaching estimates of 1 in 59.¹ In contrast, the schizophrenia population prevalence of ~1% has remained relatively stable.² Clinical diversity in schizophrenia was already reported by Bleuler, who described schizophrenia as a ‘group of schizophrenia(s)’ suggesting that this was a disorder with many possible clinical manifestations. Autism was introduced as a term in 1911 as one of four ‘types of impairment in SZ with affectivity, association, and ambivalence’.³ Autism was later described by Kanner⁴ and Asperger,⁵ to refer to a dimension of schizoid disorders. By the 1970s, researchers had clearly defined autism and childhood schizophrenia as separate conditions.⁶

The introduction of positive and negative symptoms in the 1980s helped to delineate subgroups of schizophrenia-like manifestations and therefore subgroups of patients. Negative symptoms in schizophrenia (such as social avoidance and emotional flatness) are also partially found in autism where they may be referred to as impairments in communication and motivation.⁷ Patients with either ASD or schizophrenia present difficulties in interpreting social cues associated with eye gaze, as well as deficits in theory of mind tasks.⁸ Schizophrenia is now defined as a severe mental illness involving disordered thought and perception, with a characteristic onset in late adolescence or early adulthood.⁹

To help distinguish both conditions, a ‘trumping rule’ accompanied autism in the DSM-III: autism should not be diagnosed in the presence of delusions, hallucinations, and incoherence. Today (DSM-V), spectrum terminology in ASD unifies three previously separate (DSM-IV) diagnoses: autistic’s disorder, Asperger’s disorder, and pervasive developmental disorder-not otherwise specified (PDD-NOS). Childhood-onset schizophrenia is now a recognized subtype of schizophrenia, defined by an onset before the age of 13 years. Approximately 30% of children and adolescents with childhood-onset schizophrenia also have ASD.^{10–12}

It has been suggested that ASD and schizophrenia are extreme representations of symptomatic dimensions that extend into the normal range,^{13,14} but these putative dimensions have not yet been identified. Measures of autistic-like traits have been developed (e.g. the Social Responsiveness Scale) to examine subthreshold autistic features in other psychiatric conditions (such as schizophrenia) and non-psychiatric populations.¹⁵ Measures of social communication performed in

the general population are genetically correlated with both ASD (during middle childhood) and schizophrenia (later adolescence).¹⁶ These approaches are in line with dimensional models such as the National Institute of Mental Health’s Research Domain Criteria Project (RDoC).¹³

Comorbidities are major pitfalls in top-down studies

Psychiatric comorbidities, which are common in neuropsychiatric disorders, present major caveats for any diagnosis-first studies. When a major diagnosis is assigned to an individual, it will guide treatment and enrolment in future research projects, often ignoring comorbidities. Neuroimaging and genetics findings may relate to core features of the diagnosis of interest or the spectrum of accompanying comorbidities.

Indeed, over a third of patients with ASD meet criteria for other conditions such as obsessive-compulsive disorder (OCD), anxiety, mood disorders, intellectual disability, attention deficit hyperactivity disorder (ADHD), or epilepsy.^{17,18} Although 15–25% of youth with ADHD meet the criteria for ASD, and 50–70% of those with ASD present comorbid ADHD,¹⁹ diagnostic criteria for ADHD and ASD did not allow their simultaneous diagnosis until the latest revision of the DSM-V.²⁰ Intellectual disability, classified as an ASD specifier in the DSM-V, is likewise observed in ~35% of individuals with ASD and can confound diagnostic instruments.^{21,22} A study of comorbidity within mental disorders in 5.9 million Danish individuals showed that a prior diagnosis of schizophrenia increased the risk of additional developmental disorders (including autism and intellectual disability, hazard ratio > 15), substance use, as well as personality and behavioural disorders (hazard ratio > 10).²³ A prior diagnosis of developmental disorders increased the risk for intellectual disability (hazard ratio = 50), organic and behavioural disorders (hazard ratio > 15), and schizophrenia (hazard ratio = 8).

Comorbidities are also sex-dependent.²⁴ For example, adult females with ASD are more likely to be diagnosed with comorbid OCD, mood, or eating disorders, rather than ASD, thereby underestimating the rate of ASD in young females.

Lessons learned from top-down studies

Reproducible neuroimaging findings in autism spectrum disorder and schizophrenia are limited

The most consistent structural MRI finding in ASD is, on average, a higher total brain volume (Fig. 1). This is mainly reported before 24 months,^{33,38,46,47} but is also observed in older individuals with autism (+0.25 Cohen’s *d*).³⁹ Although debated,⁴⁸ lower volumes of the cerebellum and corpus callosum and increased CSF volume were also recurrently reported in ASD compared to controls.^{38,49}




Figure 1 Genomic variants and neuroimaging alterations associated with ASD and schizophrenia. *Top:* Common and rare genetic variants (in green and blue, respectively) associated with ASD (left) or schizophrenia (SZ, right).^{25–30} *Top middle:* Genomic variants associated with both conditions and genetic correlation between ASD and schizophrenia.²⁶ *Bottom:* Structural and resting-state functional MRI (in blue and green, respectively) intermediate brain phenotypes associated with ASD (right) or schizophrenia (left). Results were reported based on meta-analyses or from the largest study to date.^{31–42} *Bottom middle:* Shared anatomical and functional alterations associated with ASD and schizophrenia.^{43–45} BP = breakpoint; CT = cortical thickness; d = dorsal; Del = deletion; Dup = duplication; FC = functional connectivity; FPN = frontoparietal network; SA = surface area; SN = salience network; v = ventral; vol = volume.

Inconsistent findings have been reported for the hippocampus, amygdala, thalamus and basal ganglia.³⁸ Such heterogeneity and small effect sizes (Cohen’s $d < 0.3$; Fig. 2) underscore the necessity for large samples allowing subtyping strategies.⁵³

To improve reproducibility, the Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) consortium increased sample size by aggregating data from 49 scanning sites. This effort identified smaller volumes of the pallidum, putamen, amygdala, and nucleus accumbens with small effect sizes (0.13 Cohen’s d). Cortical thickness was higher in the frontal cortex and smaller in the temporal cortex (0.21 Cohen’s d).³⁹ Subsequent studies of cortical morphometry in ASD⁴⁰ reported higher mean cortical thickness (Cohen’s $d = 0.22$) compared to controls, in particular in the inferior frontal and prefrontal cortex, in the superior temporal, postcentral and posterior cingulate gyri, and the precuneus (Cohen’s $d < 0.32$). Superior temporal gyrus and inferior frontal sulcus cortical thickness were negatively correlated with age and full-scale intelligence quotient (FSIQ) in the ASD group. These two large studies provided convergent results, but authors also noted inconsistencies (cortical thickness decreases in the ENIGMA study³⁹), which in part have been reconciled by adjusting the stringency of quality checking (e.g. motion) across both studies. Asymmetry in ASD has also been under scrutiny. An ENIGMA study of 54 datasets reported cortical thickness asymmetries involving mainly the superior frontal gyrus (Cohen’s $d = 0.13$), the medial frontal, orbitofrontal, inferior temporal, and cingulate regions, that were reduced in ASD compared to controls.⁵⁴

Likewise, functional connectivity has been investigated in ASD. Resting-state functional MRI is particularly appropriate to study psychiatric paediatric population because it enables data acquisition on functional connectivity without patient participation (contrary to task-based functional MRI) and limits excessive motion during scanning. Several analytical methods applied to a large

aggregate dataset showed a widespread decrease of connectivity in ASD compared to controls across all datasets.^{55,56} Underconnectivity was predominantly observed in the default mode network (DMN; Fig. 3 and Table 1), the salience, the visual, and the auditory networks. Thalamocortical overconnectivity (in particular, between the thalamus and the sensorimotor network) is also a finding replicated in most studies.^{36,55,60} Many other findings are inconsistent across sites⁴¹ and may reflect differences in ascertainment and mechanistic heterogeneity in ASD.⁶¹ These include reduced long-range connectivity, increased short-range connectivity, and decreased homotopic connectivity.⁴¹ Furthermore, functional connectivity is a field that lacks standardization and many analytical strategies are used by different groups (e.g. whether to perform global signal regression is an ongoing debate in the field and creates discrepancies across publications).^{62,63} As an example, the largest resting-state functional MRI study in ASD identified across four datasets reproducible patterns of underconnectivity within sensorimotor networks and overconnectivity within the frontoparietal networks (Fig. 3 and Table 1) across datasets (0.2–0.6 Cohen’s d).⁶⁴ However, these results were not found by previous studies, likely due to different analytical strategies.

The ‘gradient’ analysis of human functional networks provides an additional coordinate system.⁶⁵ It has been studied in the general population, and more recently in ASD. In normative/typically developing studies, this framework identifies a smooth transition along a gradient from unimodal areas of function (sensory, auditory, motor, visual) to higher-order transmodal areas (e.g. DMN). Studies showed that both extremes of the rostrocaudal gradient were decreased in ASD.⁶⁶ Further analyses revealed cortical surface area decreases in ASD specifically within transmodal medial prefrontal and posterior cingulate regions.⁶⁶

Results have been less conflicted in schizophrenia. Although both conditions are associated with small effects, those detected in




Figure 2 Effect size across three psychiatric conditions and CNVs. Distributions of Cohen's d are represented for case-control studies in ASD, schizophrenia (SZ), ADHD and CNVs using three modalities: cortical thickness (A, D and G, from Park et al.⁵⁰ and Modenato et al.⁵¹); surface area (B, E and H, from Moreau et al.⁴⁴ and Modenato et al.⁵¹) and Functional connectivity (C, F and I, from Moreau et al.^{44,52}). The same Cohen's d distributions are presented for two large (22q11.2 and 16p11.2), one moderate (1q21.1) and one small effect size (15q11.2) deletion and duplication (D–I) from Modenato et al.⁵¹ and Moreau et al.⁵² For cortical thickness, surface area, and functional connectivity, CNVs show a much larger effect size at the global (mean shift) and regional level (spread of the Cohen's d distribution) compared with psychiatric conditions.

schizophrenia are typically 2–3-fold larger than in ASD (Fig. 2). This difference, which is puzzling as ASD and schizophrenia have similar severities and prevalence, may suggest a lower level of neuroanatomical heterogeneity in schizophrenia compared to autism. A large meta-analysis reported a global grey matter reduction that was mainly driven by the dorsomedial and orbitofrontal cortex, as well as the medial temporal, insula, thalamic, and striatal area.³¹ The ENIGMA consortium (2028 schizophrenia and 2540 controls) reported smaller hippocampus (Cohen's $d = -0.46$), amygdala (Cohen's $d = -0.31$), thalamus (Cohen's $d = -0.31$), nucleus accumbens (Cohen's $d = -0.25$), and larger pallidum (Cohen's $d = 0.21$) and lateral ventricle volumes (Cohen's $d = 0.37$).³⁴ A follow-up study (4474 schizophrenia and 5098 controls) examined cortical thickness and surface area³⁵ showing a decrease in the total surface area driven by frontal and temporal lobe regions (Cohen's $d = -0.25$). A widespread decrease in cortical thickness (Cohen's $d = -0.52$) was also reported. Adjusting for mean cortical thickness showed thinner cortex in fusiform, parahippocampal, and inferior temporal gyri, and thicker cortex in the precuneus, and superior parietal cortex (Cohen's $d = 0.25$). CT differences were greater in the group of individuals treated with antipsychotic medication and were correlated with illness duration.³⁵ Of note, treatment may play a larger role in neuroimaging studies in schizophrenia compared to ASD due to the lower frequency of medication in the latter group.

Functional imaging studies in schizophrenia show reduced mean connectivity but in the absence of large functional MRI datasets in schizophrenia, results should be interpreted with caution.^{32,67} This is predominantly observed within the DMN, ventral attention, frontoparietal, and somatomotor networks (Fig. 3 and Table 1).⁶⁸ In contrast,

the thalamus has been reported as overconnected with the somatomotor network and the middle temporal gyrus (correlated with positive symptoms) and underconnected with cerebellar regions (correlated with delusions and bizarre behaviour).^{37,69} Cerebellar (Crus-I, lobule IX and lobule X) overconnectivity has been also reported with the salience and sensorimotor networks.⁴²

An ongoing debate is whether to consider resting-state as a collection of individual states that may be captured using dynamic connectivity. Studies showed that functional networks are dominated by contributions from common organizational principles and conjunction of individual features.⁷⁰ Therefore, disease-related effects that are state-dependent might appear as highly heterogeneous because of limited temporal sampling.

Earlier top-down studies were vastly underpowered to report effects in ASD and schizophrenia (e.g. analyses of the corpus callosum volume in ASD⁴⁸), but larger studies are now yielding more reproducible findings. Small effect sizes reported in both schizophrenia and ASD might be an indicator of significant heterogeneity (Fig. 2). Several factors such as medication exposure (e.g. antipsychotic medications might modulate the functional MRI signal^{71,72}) and the stage of the disease could confound these findings. There are likely subgroups associated with different patterns of brain alterations, possibly cancelling each other out in idiopathic cohorts. Examples of such effects are 16p11.2 deletions and duplications that equally increase autism risk but are associated with mirror effects on neuroimaging traits such as the insula volume.⁷³ The subgroups and dimensions nested within conditions have however remained elusive. Furthermore, many of the alterations described above have been observed across several




Figure 3 Correspondence between brain regions and functional networks. What constitutes a core functional network is not clear, and no universal taxonomy has been adopted yet.⁵⁷ Networks have been defined at several levels of resolution including the commonly used 7-network parcellation (top right⁵⁸) compared to the 12-network MIST parcellation (bottom right⁵⁹) (https://simexp.github.io/multiscale_dashboard/index.html). See also [Table 1](#).

conditions. A core set of vulnerable brain regions and networks may be present across psychiatric diagnoses.

The polygenic architecture of autism spectrum disorder and schizophrenia

Twin studies estimate the genetic contribution to ASD and schizophrenia around 73–93% and 79%, respectively.^{74–76} Heritability estimates are, however, based on models [$P(\text{phenotype}) = G(\text{genetic}) + E(\text{environment})$] that do not take into account the interaction between G and E . These estimated values may, therefore, be inflated by mechanisms such as assortative mating or dynastic effects.⁷⁷

Most of the genetic contribution is due to common variants. Although the contribution of rare mutations to the total population liability is modest (5%), they contribute substantially to individual risk⁷⁸ and occur mostly *de novo*. They are identified in 20% of individuals with ASD^{79,80} and have important implications for carriers. Among these rare variants, copy number variants (CNVs) are routinely screened in the clinic using chromosomal microarray analysis. Sixteen recurrent CNVs have been associated with ASD (Fig. 1).^{30,81} However, studies of non-recurrent CNVs estimate that any 1 megabase deletion or duplication including coding elements increases autism risk (albeit mildly) with a mean odds ratio (OR) of 1.6 and 1.2, respectively.⁸²

Large effect size CNVs, such as the 16p11.2 deletion, are identified in 7–14% of patients with ASD.^{21,81} Rare large effect-size SNVs

are identified in 13–15% of individuals with ASD.⁸³ Exome sequencing studies have identified 102 genes conferring high risk for ASD, intellectual disability, and related neurodevelopmental conditions.^{84,85} These large risk ASD genes were enriched in the genome-wide association study (GWAS) signal of schizophrenia and educational attainment, as well as gene ontology terms including gene neuronal regulation and neuronal communication.⁸⁵

For schizophrenia, large risk variants have been harder to identify in comparison with ASD.⁸⁶ Early candidate gene studies identified rare putative large risk schizophrenia genes (e.g. *COMT*, *DISC1*, *DTNBP1*, and *NRG1*), but they were not subsequently replicated.⁸⁷ Burden analyses show that *de novo* variants distributed across many coding genes are over-represented in schizophrenia.⁸⁸ However, few genes have been robustly identified as large effect-size risk factors for schizophrenia (i.e. *SETD1A*, *NRXN1*).^{89,90} Eight CNVs have been formally associated with schizophrenia with OR ranging from 2 to 30^{9,91} and eight additional CNVs met criteria for suggestive association (Fig. 1).^{27,92} However, burden analyses have demonstrated that many more CNVs increase risk for schizophrenia.²⁷

The common-allele model posits that the psychiatric condition results from the cumulative effect of multiple common alleles with small effects. The yield of GWAS studies has significantly increased with sample size. The latest studies in ASD and schizophrenia identified five single nucleotide polymorphisms (SNPs)²⁵ and 145 SNPs,²⁹ respectively. However, predictive models suggest that as sample sizes increase, the rate of future common variant discoveries for ASD will be between those for schizophrenia and major depression.⁹³

Neuroimaging and genomic dimensions across diagnostic boundaries

Neuroimaging traits and genetic factors specific to a psychiatric diagnosis have yet to be identified. The field has, however, progressed in characterizing neural substrates and genomic variants common across disorders.

In one of the first large transdiagnostic efforts, anterior cingulate area and anterior insula were among the top regions to demonstrate shared anatomical alterations across schizophrenia, bipolar disorder, major depression, addiction, OCD, and anxiety.^{43,94} Shared alterations were the highest between psychotic disorders and minimum with anxiety and OCD. A neuroanatomical investigation of ASD, schizophrenia, and ADHD has suggested that shared dimensions may arise through alterations in functional networks responsible for processing complex cognitive traits. Patterns associated with ASD and ADHD were distributed within the DMN, while ADHD and schizophrenia patterns were preferentially observed in the ventral attentional network (Fig. 3 and Table 1).⁵⁰ The remaining components of the ASD and schizophrenia alteration profiles were distributed within the frontoparietal and limbic networks. Interestingly, thickness and surface alterations were observed within the same network, but not necessarily with the same directionality across conditions. Identifying overlap between these three conditions was difficult possibly because of the small neuroimaging effect size in ASD and ADHD, and the lower correlation between schizophrenia and these two earlier onset conditions.

Deficits in the social communication questionnaire measured in individuals with ASD, ADHD, and OCD were associated with a decrease in the right insula cortical thickness and the ventral striatum volume.⁹⁵ Larger amygdala and hippocampus volumes were associated with higher scores on the 'Reading the Mind in the Eyes Test'.⁹⁵

At the functional level, studies showed that underconnectivity in the medial prefrontal cortex, anterior and posterior cingulate cortex, as well as the precuneus, were altered along a psychosis spectrum (i.e. bipolar disorder and schizophrenia).^{67,96,97} A large

Table 1 Regions involved in the main functional networks

Networks	Seed regions included
Saliency network	Anterior insula, anterior cingulate
Frontoparietal = central executive network	Dorsolateral prefrontal cortex, posterior parietal cortex
Auditory network	Superior temporal gyrus, posterior insula dorsal, auditory region
Somatomotor network	Ventrolateral, dorsolateral, medial motor regions (precentral gyrus)
Sensorimotor network	Somatomotor and somatosensory networks (postcentral gyrus)
Limbic network	Amygdala, hippocampus, fusiform gyrus, posterior insula sulcus, temporal pole, inferior temporal gyrus and orbitofrontal cortex
Basal ganglia and thalamus	Caudate nucleus, putamen, thalamus
DMN	Ventromedian prefrontal, posterior cingulate cortices, precuneus, temporal medial lobe
Cerebellar network	Cerebellum
Ventral attention network	Right temporal-parietal junction and right ventral frontal cortex
Dorsal attention network	Intraparietal sulci and frontal eye fields
Visual network	Visual regions

See also Fig. 3.

meta-analysis⁴⁵ across eight psychiatric disorders identified shared alterations in network connectivity predominantly in the ventral salience and the frontoparietal networks, and the DMN. An underconnectivity pattern was identified between the DMN and the ventral salience network and between the frontoparietal and the salience networks. An overconnectivity pattern was found between the DMN and frontoparietal network and between the DMN and salience network.

Overall, these studies suggest that neuropsychiatric disorders may be related to similar hubs of vulnerability including the anterior cingulate cortex, the DMN, the frontoparietal network (especially prefrontal regions), and the insular cortex. Although these findings should be interpreted with caution, recurrent involvement of these brain areas could be due to their complex functions such as social cognition and executive functions,⁹⁴ in line with the RDoC and p-factor. Neuroimaging dimensional reduction such as the gradient approach⁹⁸ may help position psychiatric conditions along general dimensions.

Genetic correlations between psychiatric conditions are well-replicated findings and are much higher than what has been observed for neurological conditions.^{25,26,99,100} A recent study showed that among 146 genome-wide significant SNPs reported in ASD, ADHD, schizophrenia, bipolar disorder, major depression, anorexia nervosa, OCD, and Tourette syndrome, 109 (75%) showed association with two or more conditions and 23 with four or more neuropsychiatric disorders. These 23 SNPs were located within genes expressed in the brain from the second trimester. Modelling the joint genetic architecture of these eight conditions identified three groups of neuropsychiatric disorders: compulsive, mood, and psychotic, as well as early-onset conditions. These results suggest pleiotropic mechanisms as well as genetic dimensions spanning diagnoses.^{26,101}

Similar observations have been reported for rare variants. Twenty nine pathogenic CNVs were shared across ASD and schizophrenia, including recurrent CNVs at 12 loci (such as 1q21.1, 3q29, 15q11.2, 16p11.2, 16p13.11, 17p12, 22q11.2).¹⁰² Gene set analyses pointed towards a substantial overlap of biological pathways involved in both disorders. Identified mechanisms included synapse/neuron projection, cell adhesion/junction, MAPK signalling, transcription/gene expression regulation, and the actin cytoskeleton. Shared mechanisms have been also investigated using gene expression data. Analyses of post-mortem cortex samples revealed shared gene-expression profiles between ASD and schizophrenia, as well as bipolar disorder and schizophrenia. Shared differential expression profiles involved downregulation of neuronal

and synaptic signalling pathways with a gradient of transcriptionic severity showing the largest changes in ASD compared with schizophrenia or bipolar disorder.¹⁰³

Overall, genetic factors appear to converge early on at the transcriptional level, which may in part explain phenotypic and neuroimaging traits shared across psychiatric conditions.

Bottom-up approach: large effect genetic variants to dissect mechanisms in psychiatry

The relevance of conducting bottom-up studies emerged from the questions raised by genetic discoveries of top-down studies. First, why are mutations overrepresented in individuals with a psychiatric diagnosis, and are they related to core symptoms of the disease or to comorbidities? Second, why are mutations associated with several diagnoses (pleiotropy), and do they impact a single dimension contributing to all diagnoses?

By contrast to the top-down approach, the bottom-up recruitment based on the presence of a genetic risk factor for neuropsychiatric disorders (Fig. 4), allows for the investigation of pathways related to a particular biological risk for psychiatry irrespective of any clinical phenotype. The statistical power required to conduct bottom-up studies limits this approach to genetic variants with large enough effect size and population frequency. Clinical routine investigation using whole-genome chromosomal microarrays revealed that CNVs are present in 10–15% of children with neuropsychiatric disorders.¹⁰⁴ Many recurrent neuropsychiatric CNVs have large effect sizes (~1 Cohen's *d*; Fig. 2) on cognitive and neuroimaging traits and are natural candidates to conduct genetic first studies.

Deep phenotyping one mutation at a time

Recurrent CNVs at the 16p11.2 and 22q11.2 loci are among the most frequent high-risk mutations associated with ASD and schizophrenia. Deletions and duplications between breakpoints 4 and 5 on chromosome 16p11.2 were first linked to ASD in 2008.¹⁰⁵ Carriers of the duplication have a higher risk of developing schizophrenia (OR = 9.4).^{27,30} Both 16p11.2 deletions and duplications have been enriched in a broad spectrum of other conditions including ADHD and intellectual disability.¹⁰⁶ Genetic first studies have estimated effect sizes of -1.5 Cohen's *d* on IQ, and -1.4 Cohen's *d* on phonological memory for deletions.^{107,108} A smaller decrease in IQ is associated with duplications (-0.8 Cohen's *d*). Both CNVs do also affect social responsiveness (-3 Cohen's *d*), as well as gross and fine motor skills.^{73,109} Mirror

Box 1 What have top-down and bottom-up neuroimaging genetic studies taught us?

	Top-down studies	Bottom-up: Genetic-first studies
Effect-size on neuroimaging traits	On average, the effect sizes observed in schizophrenia, ASD, and ADHD were lower than 0.5 and 0.2 Cohen's <i>d</i> (Fig. 2A–C), while behavioural adaptive symptoms lie beyond 2 Cohen's <i>d</i> .	Moderate to large effect-sizes (> 0.8) observed in neuropsychiatric mutations were observed across cognition, behaviour and neuroimaging (Fig. 2D–F) phenotypes. Mirror gene-dosage effects on neuroimaging phenotypes highlight continuous dimensions that correlate with levels of gene expression.
	The contrast between effect-size observed in bottom-up and top-down studies provides indirect evidence of mechanistic heterogeneity in behaviourally defined psychiatric conditions. The opposing effects of deletions and duplication (often associated with the same condition) offer an example of brain imaging signals cancelling each-other out. The latter may lead to small effect neuroimaging sizes in top-down case-control studies.	
Polygenicity Low genetic specificity	Common variants in more than 1000 genes have been associated with risk for ASD and schizophrenia. Studies have estimated that every mega base of the genome encompasses common variation associated with schizophrenia. 16 and 21 CNVs, as well as 145 and 5 SNPs, have been associated with ASD and schizophrenia, respectively (Fig. 1). Models suggest that (i) any 1 megabase CNV (including coding genes) in the genome increases the risk of ASD; and (ii) 10 000 genes negatively impact cognitive ability when deleted.	Multiple genes with small individual effects appear to contribute to the overall neurodevelopmental symptoms of most neuropsychiatric CNVs. Many CNVs appear to impact similar traits such as cognitive abilities. Neuroimaging studies suggest that single genes and CNVs may potentially converge on shared patterns of anatomical and functional alterations.
	Rare and common variants in the genome show redundant associations with cognitive traits, psychiatric conditions and potentially neuroimaging traits.	
Genetic and neuroimaging correlations Pleiotropy	Genetic correlation is widespread across psychiatric conditions and is much higher than what is observed across neurological disorders. Among 146 genome-wide significant SNPs reported in at least one of eight psychiatric conditions, 109 showed association with two or more disorders including ASD and schizophrenia.	Large effect size rare variants including CNVs and SNVs are associated with a broad spectrum of phenotypes, and multiple diagnoses including ASD, schizophrenia, ADHD.
	Pleiotropic effects of rare and common genomic variants likely underlie the high rate of clinical comorbidities in psychiatry as well as the plurality of brain endophenotypes associated with a particular set of symptoms	

anthropometric phenotype has been reported with deletions mainly associated with obesity and macrocephaly and duplications associated with underweight, and microcephaly. Again, effects are large ranging from 0.8 to 1 Cohen's *d*.^{107,108,110,111} Neuroimaging analyses reported negative gene-dosage effects on total brain volume, total grey and white matter with again similar large effect sizes.¹¹² Once effects on global volumes are taken into account, a mirror negative gene dosage effect was observed for the insula volume.⁷³ Other altered regions were only observed in deletions: transverse temporal gyrus, the calcarine cortex (Cohen's *d* > 1), superior and middle temporal gyrus (Cohen's *d* < -1) or in duplications: caudate and hippocampus (control > duplication, -0.5 > Cohen's *d* > -1).⁷³ At the functional level, a negative gene dosage effect on global connectivity was identified. After accounting for global signal, regional alterations in deletion included a thalamic-sensorial overconnectivity, impairment of frontoparietal network with temporoparietal regions, and strong disturbance of the posterior insula, the presupplementary motor cortex, and the basal ganglia (beta values from -0.8 to 1.4

z-scores).^{44,113} Duplications had a smaller effect on connectivity and mostly involved the amygdala-hippocampus complex, the cerebellum, and the basal ganglia.

Deletion at the 22q11.2 locus is the largest risk factor for schizophrenia (OR = 68) and up to 30% of adolescents and adults will develop psychosis.^{27,114,115} Children with 22q11.2 deletion have also a high risk of developing ASD (OR = 32),³⁰ ADHD, and anxiety disorders.^{116,117} Duplications are less severe and are inherited in 70% of the cases (compared to deletions which are *de novo* in over 90% of individuals). While studies suggested a protective effect for schizophrenia¹¹⁸ (OR = 0.15),²⁷ the duplication has been associated with a wide range of phenotypes, including ASD, psychomotor development, speech delay, and cognitive deficits.¹¹⁸ Ascertainment bias remains an issue in the study of genomic disorders which are often recruited in the clinic. Although this is particularly true for smaller effect size variants but may also apply to a lesser degree to 22q11.2.¹¹⁹

ENIGMA 22q11.2 deletion T-weighted studies reported a global decrease in surface area and an increase in mean cortical

thickness (Cohen's d : surface area = 1, cortical thickness = 0.6), particularly in temporal and cingulate cortices.¹²⁰ Subcortical analyses showed decreased volumes and abnormal shape of the thalamus, putamen, hippocampus, and amygdala volumes (Cohen's d = -0.9), as well as a greater lateral ventricle volume.¹²¹ The duplication shows an opposing pattern for mean cortical thickness, intracranial volume,¹²² and the hippocampus volume. Functional MRI studies have shown mirror effects at the global connectivity level. Underconnectivity between DMN, limbic, and frontoparietal networks is observed in deletions compared to control.^{44,123} Studies replicated a thalamocortical overconnectivity involving somatomotor regions and underconnectivity involving default mode network. The opposite effect was observed for the hippocampus in regard to somatomotor and frontoparietal network connectivity.^{44,124}

However, it remains unclear if rare variants such as 16p11.2 and 22q11.2 represent mechanistic exceptions or if they may delineate dimensions that are generalized to idiopathic ASD and schizophrenia. This has been investigated at the functional connectivity level. The 16p11.2 deletion connectivity signature showed similarities with individuals diagnosed as either idiopathic schizophrenia or ASD and was associated with higher cognitive and behavioural impairments. Connectivity similarities were driven by the thalamus, the basal ganglia, and the cingulate areas. The 22q11.2 deletion connectivity profile showed similarities with individuals with idiopathic schizophrenia, ASD, and to a lesser extent with ADHD in particular through the thalamus, temporal pole, putamen, and the posterior insula.⁴⁴ The thalamus and somatomotor regions played a critical role in dysconnectivity observed across both deletions and idiopathic psychiatric conditions.

Studies have sought to identify major genes driving phenotypic effects in CNV carriers to understand cellular mechanisms that give rise to the risk conferred by these variants. The 16p11.2 chromosomal region contains 29 unique genes and none of them has been formally linked to the 16p11.2 clinical phenotype.¹²⁵ However, a smaller critical region of five genes, which includes *TAOK2* and *KCTD13*, has been identified. Animal studies on *TAOK2* reported dosage-dependent effects including changes in brain size and neural connectivity.¹²⁶ Loss of *TAOK2* activity was related to a reduction in RhoA activation, suggesting that this pathway is a mediator of *TAOK2*-dependent synaptic development. Of note, *TAOK2* is interacting with *KCTD13* in the RhoA signalling pathway, and with *MAPK3*.⁸⁴ The overexpression of the human *KCTD13* gene in zebrafish embryos induces a decrease in head size whereas deletion of the zebrafish orthologue yields a macrocephalic phenotype,¹²⁷ but follow-up studies did not replicate *KCTD13* findings.¹²⁵

Among the 50 genes within the 22q11.2 locus,¹¹⁴ *COMT*, *TBX1*, *SEPT5*, and *DGCR8* were studied as putative critical drivers of the phenotype but results remain inconsistent.¹²⁸ Importantly, an excess of *de novo* loss of function mutations has not been reported in any of the genes within the 16p11.2 and 22q11.2 regions. Overall, these studies show that association evidence for a CNV does not automatically imply that a single or even few genes are driving the effects.¹²⁹

Common and specific effects of genomic variants on intermediate brain phenotypes

Single variant approaches reported in the previous chapter can only be applied to a few recurrent pathogenic variants frequent enough to establish a case-control study design. Thus, the effects of most rare deleterious variants remain undocumented. Single variant studies are therefore at odds with the extreme polygenicity of schizophrenia and ASD highlighted by GWAS discussed in the top-down approach. Several studies have suggested that every megabase of the genome contains common variation associated with increased risk for schizophrenia. This infinitesimal

model also referred to as omnigenic applies to ASD and evidence shows that any megabase deletion including coding genes increases the risk for this condition.⁸² In this context, two non-exclusive hypotheses could be pursued: (i) an infinite number of disease-associated variants map onto an infinite number of neuroimaging patterns; and (ii) variants converge on a parsimonious set of large scale network alterations. The first hypothesis alone appears improbable because ASD and schizophrenia case-control neuroimaging studies would have otherwise obtained no result.

In the effort to characterize specific and shared effects of CNVs on neuroimaging outcomes, a first cross-genetic study clustered neuro-anatomical alterations across 26 different genetic mouse models of autism (including 16p11.2 CNVs, *MECP2*, *NRXN1*, and *FMR1*).¹³⁰ Regional differences (relative to total brain volume) were heterogeneous but some regions were recurrently affected across models including the temporoparietal area, the cerebellar cortex, the frontal lobe, the hypothalamus, and the striatum. The authors clustered anatomical alterations and identified three distinct subgroups driven respectively by the limbic system, white matter structures/basal ganglia/thalamus, and cerebellar regions. Knockout mouse models from this study seemed to recapitulate the heterogeneity seen with the imaging findings in autism patients.

Similar studies in humans have been extremely difficult to implement because of the lack of data on individuals with genomic variants. Recent access to neuroimaging genetic data in the UK Biobank enabled the study of 12 schizophrenia-associated CNVs in the general population ($n = 49$ unaffected CNV carriers with schizophrenia, including 16p11.2, 22q11.2, *NRXN1*, 15q11.2, and 1q21.1 CNVs).¹³¹ The thalamus, the hippocampus, and the nucleus accumbens showed decreased volumes in CNV schizophrenia carriers. Thalamic and hippocampal volumes appeared to mediate effects on cognitive performances. A functional resting-state study of 502 carriers of eight neuropsychiatric CNVs (22q11.2, 16p11.2, 15q11.2, and 1q21.1 CNVs) showed that deletions and duplications had strong effects on connectivity. The level of brain dysfunction was also associated with the known levels of risk conferred by mutations. Connectivity signatures of 16p11.2 and 22q11.2 deletions showed similarities across several networks involving the frontoparietal, DMN, ventral attentional, and somatomotor networks.⁴⁴ Dysconnectivity profiles across eight CNVs and idiopathic ASD, schizophrenia, and ADHD were summarized by three latent components involving the thalamus, the temporal pole, the anterior cingulate, and the ventromedial prefrontal cortex. The level of similarity between CNVs and idiopathic conditions was associated with mutation severity and was driven by the thalamus, and the posterior cingulate cortex, previously identified as hubs in transdiagnostic psychiatric studies (cf. 'Lessons learned from top-down studies' section). Beyond categorical diagnoses, CNV connectivity signatures were correlated with measures of autism severity and IQ.⁴⁴

The extreme polygenicity of ASD and schizophrenia suggests that broad groups of rare and common variants share cognitive effects and neuroimaging patterns. A weighted linear model was developed to estimate the effect of CNVs on IQ using scores of intolerance to protein loss of function in a dataset of 24 000 individuals from unselected and psychiatric cohorts with cognitive assessments.^{132–134} These models could predict the effect size of any CNV with 80% accuracy. Deletions of > 50% of the coding genome negatively impacted IQ, and this is consistent with infinitesimal/omnigenic models. The same linear weighted model using scores of intolerance to protein loss-of-function was used to explain functional connectivity across CNVs at 18 genomic loci in 502 carriers and 4427 non-carrier individuals. Deletions measured with scores of intolerance to probability of being loss-of-function intolerant (pLI) were associated with a general connectivity signature involving the thalamus, the anterior cingulate cortex, and the somatomotor network. This general deletion signature




Figure 4 Top-down versus bottom-up approaches. The genetic-first, bottom-up approach (right) can build models/signatures from a lower level in the hierarchy (e.g. intermediate brain phenotype), and then asks questions about how such low-level models can explain observations higher up in the hierarchy (clinical manifestations).

was correlated with lower general intelligence and higher autism severity scores in unselected, ASD, and ADHD cohorts.

A similar approach showed that schizophrenia relative-risk was correlated with diminished performance on at least one cognitive test. This approach was also applied to 21 carriers of either 22q11.2, 15q11.2, 1q21.1, 16p11.2, and 17q12 CNVs and 15 non-carriers showing that macro and microstructural properties of the cingulum bundles were associated with schizophrenia relative-risk.¹³⁵

Bottom-up approaches have also been conducted in the general population using the aggregated genetic effect of common variants (polygenic risk scores). Polygenic risk scores use a set of trait-related SNPs that may not achieve significance at the individual level but collectively may explain a portion of the trait variance.¹³⁶ Negative associations were observed in the general population between schizophrenia-polygenic risk score and mean cortical thickness, insular lobe^{137–139} and, frontotemporal cortical thickness as well as left hippocampus volume.¹⁴⁰ This demonstrated again that some neuro-anatomical alterations are shared between individuals at risk for schizophrenia and diagnosed with schizophrenia. Of note, studies (Generation R) of polygenic risk scores for ASD, schizophrenia, ADHD, bipolar disorder, and major depression, did not yield any results.¹⁴¹ This may be due to the fact that as opposed to bottom-up studies of single mutations, polygenic risk scores are likely to be mechanistically heterogeneous, diluting the neuroimaging signal. Computing polygenic scores informed by biological and brain processes (e.g. genes highly expressed in sensory-motor regions) has considerable potential to parse out the contribution of specific pathways to alterations of brain architecture (Fig. 5).

Larger GWAS studies will improve the amount of variance explained by polygenic risk scores and will increase the relevance of bottom-up neuroimaging genetics studies using common variants.^{137–139} Such scores can capture individual-level variation and will be particularly appropriate for future predictive models.¹⁴⁵

Future directions: linking microscale and macroscale observations

Gene expression data from the brain at the developmental, spatial and cell type levels provides highly granular information to annotate the brain function genetic variants at the micro- and macroscale levels (Fig. 5). A major hypothesis is that patterns of gene expression will allow us to understand the relationship between mutations and their effects on brain architecture and behaviour. Work from the Allen Institute suggests that a set of genes constitutes the core transcriptional machinery of the human brain.¹⁴⁶ Thirty-two modules of co-expressed genes were




Figure 5 Integrating top-down and bottom-up strategies in neuroimaging genomics. We propose a systematic investigation of a broad spectrum of neuropsychiatric variants to identify dimensions underlying idiopathic conditions. Multiscale and multimodal studies using multivariate approaches would allow for the identification of latent brain dimensions that best explain the relationships between genomic variants, biological processes, psychiatric conditions, and cognitive traits. Neuroimaging proxies of specific biological processes are identified through bottom-up approaches using individuals who carry mutations in genes involved in defined gene sets (akin to a polygenic score). Computing polygenic scores informed by biological and brain processes (e.g. genes highly expressed in sensory-motor regions) has considerable potential to parse out the contribution of specific pathways to alterations of brain architecture. Multivariate approaches such as canonical correlation analysis or structural equation modelling¹⁴² will allow investigating the relationship between genomic variants, neuroimaging features, psychiatric conditions, and behavioural traits. BIP = bipolar disorder; CCA = canonical correlation analysis; GE = gene expression components¹⁴³; IQ = intelligence quotient; pLI = probability of being loss-of-function intolerant; PLS = partial least square regression; PRS-SZ = polygenic risk score for schizophrenia; Pvalb = parvalbumin^{143,144}; SEM = structural equation modelling; SZ = schizophrenia. See also Table 1.

identified—based on their spatial patterns of expression—highlighting a genome-wide redundancy. They were enriched for specific cell types, intracellular components, and associated with neurodevelopmental and degenerative conditions.¹⁴⁶ These modules recapitulate large-scale gradients of brain organization.⁹⁸ This canonical transcriptional organization of the genome (the default gene network¹⁴⁶) is also highly correlated with the brain's functional network architecture, such as with the default mode network and the principal gradient of macroscale cortical organization.^{65,143}

Genomic variants in genes with a similar cortical organization or temporal pattern may lead to a shared set of brain alterations at the structural and functional levels. In other words, patterns of gene expression may predict patterns of neuroimaging alterations in carriers of CNVs and other genomic variants. Recently spatial patterns of cortical anatomy changes in individuals with 22q11.2 deletions, as well as aneuploidies (sex chromosomes and Down syndrome), were found to be correlated with cortical spatial expression of genes within the 22q11.2, X and Y chromosomes.¹⁴⁷ The same observations have been reported at the functional connectivity level, by testing the association between connectivity-signatures of 22q11.2 and 16p11.2 deletion profiles and the brain expression patterns of genes encompassed in these genomic loci.⁴⁴ However, it appears that these relationships are not specific. For example, the spatial brain expression pattern of 1834 genes (genome-wide false discovery rate) were correlated with the




Figure 6 Historical timeline in neuroimaging genetics. Many advances in neuroimaging genomics have been made by large-scale initiatives and cohort studies, such as the Autism Brain Imaging Data Exchange (ABIDE),⁵⁵ the Psychiatric Genomics Consortium (PGC),¹⁵⁹ the Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) Consortium¹⁶⁰ and the UK Biobank.¹⁶¹ These collaborative initiatives, among others, facilitate advances in psychiatry by providing large brain imaging and genomics datasets to the research community worldwide. Human Genome Project (HGP)¹⁶²; Neuroimaging Tools and Resources Collaboratory (NITRC platform); Psychiatric Genomics Consortium (PGC)¹⁵⁹; Alzheimer's Disease Neuroimaging Initiative (ADNI)¹⁶³; 1000 Genomes¹⁶⁴; ADHD-200¹⁶⁵; Open fMRI¹⁶⁶; Human Brain Project (HBP)¹⁶⁷; ENIGMA Consortium = Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA Consortium)¹⁶⁰; = Autism Brain Imaging Data Exchange (ABIDE-1)⁵⁵; NeuroVault¹⁶⁸; UK Biobank¹⁶¹; HCP = Human Connectome Project (HCP)¹⁶⁹; PING = Pediatric Imaging; Neurocognition; and Genetics (PING)¹⁷⁰; SchizConnect¹⁷¹; EU-Aims¹⁷²; Adolescent Brain Cognitive Development (ABCD).¹⁷³

22q11.2 functional brain connectivity profile. Indeed, many genes share similar spatial and temporal expression patterns, which may potentially explain the polygenic architecture of brain organization and psychiatric condition as well as the shared variance of cortical alterations across psychiatric disorders.¹⁴⁸

The cytoarchitecture of the human brain may also help understand the link between genomic variants, their associated brain alterations and psychiatric conditions. For example, genes preferentially expressed in oligodendrocytes show a cortical distribution in their expression that is positively correlated with intracortical myelination measured by magnetization transfer.¹⁴⁹ Brain alterations caused by CNVs and sex chromosome aneuploidies have also been associated with gene expression distributed along gradients of cell types.¹⁴⁷ A similar approach has also linked cell types to patterns of brain alterations associated with ASD, ADHD, bipolar disorder, schizophrenia, OCD, and major depression. This 'virtual histology' approach reveals that the cortical expression patterns of pyramidal, microglia, astrocyte genes were correlated with cortical thickness alteration maps of eight psychiatric conditions.¹⁴⁸

Although temporal expression during brain development is a dimension that is likely to impact brain architecture, it has not yet been associated with MRI alteration observed in carriers of CNVs and genomic variants. These exciting attempts to bridge macro- and micro-scale observations are initiating fruitful collaborations between genomics, neurobiology, computational and evolutionary neuroscience.

Functional dimensions disturbed across psychiatric conditions may also be distributed through these modules of co-expression

and functional gradients.¹⁵⁰ Such properties might be related to emerging properties of the genome and the recent evolution of the human brain.^{151,152}

Conclusion: what have we learned and what are the next steps?

Early neuroimaging genomic studies in psychiatry were plagued by small sample sizes and inappropriate candidate gene strategies. Studies of psychiatric disorders were performed on the assumption of relative specificity (Box 1). With access to larger datasets in the past years, both top-down and bottom-up neuroimaging-genomics studies have gained traction with increased reproducibility of nature and effect-size of the alterations. The effect sizes of rare variants on neuroimaging endophenotypes are concordant with effects previously measured for the same variants on brain structure, cognitive and behavioural traits.^{73,133} This is in striking contrast with the effect sizes observed for functional connectivity and brain structure in schizophrenia, ASD, and ADHD, which are 3–5-fold lower (Fig. 2).^{35,39}

This surprising discordance of effect-sizes observed between bottom-up (rare variants) and top-down studies (idiopathic conditions) underscore the necessity to dissect results from case-control studies conducted in idiopathic conditions with results from large-effect size rare variants. We propose a genetically-informed stratification by systematically investigating a broad spectrum of neuropsychiatric variants. This should allow for the identification of latent dimensions in idiopathic conditions.

The shared neuroimaging dimensions identified across psychiatric conditions are in line with the genetic correlation demonstrated between the same conditions as well as pleiotropic effects of genomic variants (Fig. 1). Findings also suggest a staggering diversity of brain endophenotypes across different genomic variants and idiopathic psychiatric conditions. Therefore, the time has not yet arrived to draw firm conclusions about the nature of the potential neuroimaging convergence (or lack thereof), across genetic risk and psychiatric conditions.

The neuroimaging field is increasingly moving towards harmonization using systematic analytical methods, atlas, and data structure^{58,153,154} as well as reporting standards including effect-sizes and un-thresholded beta map (Poldrack Nature). Large efforts have been in building platforms to associate imaging modalities and genetic data.^{155–158}

Only a few datasets currently allow neuroimaging genomic studies (Fig. 6): UKBB¹⁶¹ and ABCD¹⁷³ are large population cohorts with great potential to study genomic variation and neuroimaging phenotypes, but they include few individuals with mental illnesses and behavioural deficits. EU-AIMS is among the few psychiatric cohorts integrating genomics, neuroimaging and cognitive data, in ~250 individuals with autism.¹⁷² Given our assumptions on the mechanistic heterogeneity in ASD, one would expect that a neuroimaging genomic dataset of several thousand individuals with autism would be required to provide the power to investigate brain-molecular dimensions. Of note, there are currently no neuroimaging genomic cohorts in schizophrenia that are available to the community. The ENIGMA consortium¹⁶⁰ has also been instrumental in moving the field and has provided well-powered meta-analytic studies.

Neuroimaging genetic studies investigating large effect size mutations are lagging behind those focused on common variation. Closing this gap will require investing in new large scale cohorts with exome/genome sequencing data collected in individuals with a broad spectrum of psychiatric conditions. Cohorts with such data include UKBB and EU-AIMS. Alternative strategies include gene cohorts ascertaining individuals with previously identified large effect size neuropsychiatric variants such as ENIGMA-CNV, ENIGMA 22q11.2, and Quebec 1000 families. These efforts should provide significant power to associate brain mechanisms to genomic variants, molecular mechanisms, and mental illnesses. They will likely improve predictive modelling at the individual level and guide the development of mechanistically informed predictive tests with clinical utility.

Acknowledgements

We thank M. T. Park for providing Cohen's *d* data for ASD, schizophrenia, and ADHD from his paper.⁵⁰ We used them in Fig. 2.

Funding

This research was supported by the Brain Canada Multi investigator research initiative (MIRI), funds from the Institute of Data Valorization (IVADO). S.J. is supported by the Canadian Institute of Health Research CIHR_400528 and the The Institute of Data Valorization (IVADO) through the Canada First Research Excellence Fund, Healthy Brains for Healthy Lives through the Canada First Research Excellence Fund. P.B. is a fellow ('Chercheur boursier Junior 2') of the 'Fonds de recherche du Québec—Santé'.

Competing interests

P.M.T. is supported in part by a grant from Biogen, Inc. (Boston, USA) for research unrelated to this manuscript.

References

- Baio J, Wiggins L, Christensen DL, et al. Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2014. *MMWR Surveill Summ.* 2018;67:1–23.
- Rødgaard E-M, Jensen K, Vergnes J-N, Soulières I, Mottron L. Temporal changes in effect sizes of studies comparing individuals with and without autism: A meta-analysis. *JAMA Psychiatry.* 2019;76(11):1124.
- Bleuler E. *Dementia praecox oder Gruppe der Schizophrenien.* Deuticke; 1911.
- Kanner L. Autistic disturbances of affective contact. *Nervous Child.* 1943;2:217–250.
- Asperger H. Die "Autistischen Psychopathen" im Kindesalter. *Archiv Für Psychiatrie Und Nervenkrankheiten.* 1944;117(1):76–136.
- Chisholm K, Lin A, Abu-Akel A, Wood SJ. The association between autism and schizophrenia spectrum disorders: A review of eight alternate models of co-occurrence. *Neurosci Biobehav Rev.* 2015;55:173–183.
- Craddock N, Owen MJ. The Kraepelinian dichotomy - going, going... but still not gone. *Br J Psychiatry.* 2010;196(2):92–95.
- Sasson NJ, Pinkham AE, Weittenhiller LP, Faso DJ, Simpson C. Context effects on facial affect recognition in schizophrenia and autism: Behavioral and eye-tracking evidence. *Schizophr Bull.* 2016;42(3):675–683.
- Bearden CE, Forsyth JK. The many roads to psychosis: Recent advances in understanding risk and mechanisms. *F1000Res.* 2018;7:1883.
- Canitano R, Pallagrosi M. Autism spectrum disorders and schizophrenia spectrum disorders: Excitation/inhibition imbalance and developmental trajectories. *Front Psychiatry.* 2017;8:69.
- Driver DI, Gogtay N, Rapoport JL. Childhood onset schizophrenia and early onset schizophrenia spectrum disorders. *Child Adolesc Psychiatr Clin N Am.* 2013;22(4):539–555.
- Rapoport J, Chavez A, Greenstein D, Addington A, Gogtay N. Autism spectrum disorders and childhood-onset schizophrenia: Clinical and biological contributions to a relation revisited. *J Am Acad Child Adolesc Psychiatry.* 2009;48(1):10–18.
- Insel T, Cuthbert B, Garvey M, et al. Research domain criteria (RDoC): Toward a new classification framework for research on mental disorders. *Am J Psychiatry.* 2010;167(7):748–751.
- Owen MJ, O'Donovan MC. Schizophrenia and the neurodevelopmental continuum: Evidence from genomics. *World Psychiatry.* 2017;16(3):227–235.
- Kincaid DL, Doris M, Shannon C, Mulholland C. What is the prevalence of autism spectrum disorder and ASD traits in psychosis? A systematic review. *Psychiatry Res.* 2017;250:99–105.
- St Pourcain B, Robinson EB, Anttila V, et al.; iPSYCH-SSI-Broad Autism Group. ASD and schizophrenia show distinct developmental profiles in common genetic overlap with population-based social communication difficulties. *Mol Psychiatry.* 2018;23(2):263–270.
- Jacob S, Wolff JJ, Steinbach MS, Doyle CB, Kumar V, Elison JT. Neurodevelopmental heterogeneity and computational approaches for understanding autism. *Transl Psychiatry.* 2019;9(1):63.
- Joshi G, Petty C, Wozniak J, et al. The heavy burden of psychiatric comorbidity in youth with autism spectrum disorders: A large comparative study of a psychiatrically referred population. *J Autism Dev Disord.* 2010;40(11):1361–1370.
- Antshel KM, Zhang-James Y, Wagner KE, Ledesma A, Faraone SV. An update on the comorbidity of ADHD and ASD: A focus on clinical management. *Expert Rev Neurother.* 2016;16(3):279–293.
- Ramtekkar UP. DSM-5 changes in attention deficit hyperactivity disorder and autism spectrum disorder: Implications for comorbid sleep issues. *Children.* 2017;4(8):62–64.

21. Geschwind DH, State MW. Gene hunting in autism spectrum disorder: On the path to precision medicine. *Lancet Neurol*. 2015;14(11):1109–1120.
22. Volkmar FR, McPartland JC. From Kanner to DSM-5: Autism as an evolving diagnostic concept. *Annu Rev Clin Psychol*. 2014;10:193–212.
23. Plana-Ripoll O, Pedersen CB, Holtz Y, et al. Exploring comorbidity within mental disorders among a Danish National Population. *JAMA Psychiatry*. 2019;76(3):259–270.
24. Loomes R, Hull L, Mandy WPL. What is the male-to-female ratio in autism spectrum disorder? A systematic review and meta-analysis. *J Am Acad Child Adolesc Psychiatry*. 2017;56(6):466–474.
25. Grove J, Ripke S, Als TD, et al.; 23andMe Research Team. Identification of common genetic risk variants for autism spectrum disorder. *Nat Genet*. 2019;51(3):431–444.
26. Lee PH, Anttila V, Won H, et al. Genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders. *Cell*. 2019;179(7):1469–1482.e11.
27. Marshall CR, Howrigan DP, Merico D, et al.; CNV and Schizophrenia Working Groups of the Psychiatric Genomics Consortium. Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. *Nat Genet*. 2017;49(1):27–35.
28. Moreno-De-Luca D, Moreno-De-Luca A, Cubells JF, Sanders SJ. Cross-disorder comparison of four neuropsychiatric CNV loci. *Curr Genet Med Rep*. 2014;2(3):151–161.
29. Pardiñas AF, Holmans P, Pocklington AJ, et al.; CRESTAR Consortium. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. *Nat Genet*. 2018;50(3):381–389.
30. Sanders SJ, Sahin M, Hostyk J, et al. A framework for the investigation of rare genetic disorders in neuropsychiatry. *Nat Med*. 2019;25(10):1477–1487.
31. Fornito A, Yücel M, Patti J, Wood SJ, Pantelis C. Mapping grey matter reductions in schizophrenia: An anatomical likelihood estimation analysis of voxel-based morphometry studies. *Schizophr Res*. 2009;108(1-3):104–113.
32. Fornito A, Zalesky A, Pantelis C, Bullmore ET. Schizophrenia, neuroimaging and connectomics. *Neuroimage*. 2012;62(4):2296–2314.
33. Hazlett HC, Poe MD, Gerig G, et al. Early brain overgrowth in autism associated with an increase in cortical surface area before age 2 years. *Arch Gen Psychiatry*. 2011;68(5):467–476.
34. van Erp TGM, Hibar DP, Rasmussen JM, et al. Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. *Mol Psychiatry*. 2016;21(4):547–553.
35. van Erp TGM, Walton E, Hibar DP, et al.; Karolinska Schizophrenia Project. Cortical brain abnormalities in 4474 individuals with schizophrenia and 5098 control subjects via the enhancing neuro imaging genetics through meta analysis (ENIGMA) consortium. *Biol Psychiatry*. 2018;84(9):644–654.
36. Woodward ND, Giraldo-Chica M, Rogers B, Cascio CJ. Thalamocortical dysconnectivity in autism spectrum disorder: An analysis of the Autism Brain Imaging Data Exchange. *Biol Psychiatry Cogn Neurosci Neuroimaging*. 2017;2(1):76–84.
37. Ferri J, Ford JM, Roach BJ, et al. Resting-state thalamic dysconnectivity in schizophrenia and relationships with symptoms. *Psychol Med*. 2018;48(15):2492–2499.
38. Pagnozzi AM, Conti E, Calderoni S, Frapp J, Rose SE. A systematic review of structural MRI biomarkers in autism spectrum disorder: A machine learning perspective. *Int J Dev Neurosci*. 2018;71:68–82.
39. van Rooij D, Anagnostou E, Arango C, et al. Cortical and subcortical brain morphometry differences between patients with autism spectrum disorder and healthy individuals across the lifespan: Results from the ENIGMA ASD working group. *Am J Psychiatry*. 2018;175(4):359–369.
40. Bedford SA, Park MTM, Devenyi GA, et al.; MRC AIMS Consortium. Large-scale analyses of the relationship between sex, age and intelligence quotient heterogeneity and cortical morphometry in autism spectrum disorder. *Mol Psychiatry*. 2020;25(3):614–628.
41. King JB, Prigge MBD, King CK, et al. Generalizability and reproducibility of functional connectivity in autism. *Mol Autism*. 2019;10:27.
42. Kim D-J, Moussa-Tooks AB, Bolbecker AR, et al. Cerebellar-cortical dysconnectivity in resting-state associated with sensorimotor tasks in schizophrenia [Internet]. *Hum Brain Mapp*. 2020;41(11):3119–3132.
43. Goodkind M, Eickhoff SB, Oathes DJ, et al. Identification of a common neurobiological substrate for mental illness. *JAMA Psychiatry*. 2015;72(4):305–315.
44. Moreau CA, Urchs SGW, Kuldeep K, et al. Mutations associated with neuropsychiatric conditions delineate functional brain connectivity dimensions contributing to autism and schizophrenia. *Nat Commun*. 2020;11(1):1–12.
45. Sha Z, Wager TD, Mechelli A, He Y. Common dysfunction of large-scale neurocognitive networks across psychiatric disorders. *Biol Psychiatry*. 2019;85(5):379–388.
46. Courchesne E, Karns CM, Davis HR, et al. Unusual brain growth patterns in early life in patients with autistic disorder: An MRI study. *Neurology*. 2001;57(2):245–254.
47. Li D, Karnath H-O, Xu X. Candidate biomarkers in children with autism spectrum disorder: A review of MRI studies. *Neurosci Bull*. 2017;33(2):219–237.
48. Lefebvre A, Beggiano A, Bourgeron T, Toro R. Neuroanatomical diversity of corpus callosum and brain volume in autism: Meta-analysis, analysis of the autism brain imaging data exchange project, and simulation. *Biol Psychiatry*. 2015;78(2):126–134.
49. Valenti M, Pino MC, Mazza M, Panzarino G, Di Paolantonio C, Verrotti A. Abnormal structural and functional connectivity of the corpus callosum in autism spectrum disorders: A review. *Rev J Autism Dev Dis*. 2020;7(1):46–62.
50. Park MTM, Raznahan A, Shaw P, Gogtay N, Lerch JP, Chakravarty MM. Neuroanatomical phenotypes in mental illness: Identifying convergent and divergent cortical phenotypes across autism, ADHD and schizophrenia. *J Psychiatry Neurosci*. 2018;43(3):201–212.
51. Modenato C, Kumar K, Moreau C, et al. Neuropsychiatric copy number variants exert shared effects on human brain structure. *medRxiv*. [Preprint] doi:10.1101/2020.04.15.20056531
52. Moreau C, Huguet G, Urchs S, et al. The general impact of haploinsufficiency on brain connectivity underlies the pleiotropic effect of neuropsychiatric CNVs. *medRxiv*. [Preprint] doi:10.1101/2020.03.18.20038505
53. Abraham A, Milham MP, Di Martino A, et al. Deriving reproducible biomarkers from multi-site resting-state data: An Autism-based example. *Neuroimage*. 2017;147:736–745.
54. Postema MC, van Rooij D, Anagnostou E, et al. Altered structural brain asymmetry in autism spectrum disorder in a study of 54 datasets. *Nat Commun*. 2019;10(1):4958.
55. Di Martino A, Yan C-G, Li Q, et al. The autism brain imaging data exchange: Towards a large-scale evaluation of the intrinsic brain architecture in autism. *Mol Psychiatry*. 2014;19(6):659–667.
56. Lau WKW, Leung M-K, Lau BW. Resting-state abnormalities in autism spectrum disorders: A meta-analysis. *Sci Rep*. 2019;9(1):3892.
57. Uddin LQ, Yeo BTT, Spreng RN. Towards a universal taxonomy of macro-scale functional human brain networks. *Brain Topogr*. 2019;32(6):926–942.
58. Yeo BTT, Krienen FM, Sepulcre J, et al. The organization of the human cerebral cortex estimated by intrinsic functional connectivity. *J Neurophysiol*. 2011;106(3):1125–1165.

59. Urcus S, Armoza J, Moreau C, et al. MIST: A multi-resolution parcellation of functional brain networks. *MNI Open Res.* 2019;1:3.
60. Tomasi D, Volkow ND. Reduced local and increased long-range functional connectivity of the thalamus in autism spectrum disorder. *Cereb Cortex.* 2019;29(2):573–585.
61. He Y, Byrge L, Kennedy DP. Nonreplication of functional connectivity differences in autism spectrum disorder across multiple sites and denoising strategies. *Hum Brain Mapp.* 2020;41(5):1334–1350.
62. Li J, Bolt T, Bzdok D, et al. Topography and behavioral relevance of the global signal in the human brain. *Sci Rep.* 2019;9(1):14286.
63. Murphy K, Fox MD. Towards a consensus regarding global signal regression for resting state functional connectivity MRI. *Neuroimage.* 2017;154:169–173.
64. Holiga S, Hipp JF, Chatham CH, et al. Patients with autism spectrum disorders display reproducible functional connectivity alterations. *Sci Transl Med.* 2019;11(481):eaat9223.
65. Margulies DS, Ghosh SS, Goulas A, et al. Situating the default-mode network along a principal gradient of macroscale cortical organization. *Proc Natl Acad Sci U S A.* 2016;113(44):12574–12579.
66. Hong S-J, de Wael RV, Bethlehem RAI, et al. Atypical functional connectome hierarchy in autism. *Nat Commun.* 2019;10(1):1022.
67. Fornito A, Bullmore ET. Reconciling abnormalities of brain network structure and function in schizophrenia. *Curr Opin Neurobiol.* 2015;30:44–50.
68. Dong D, Wang Y, Chang X, Luo C, Yao D. Dysfunction of large-scale brain networks in schizophrenia: A meta-analysis of resting-state functional connectivity. *Schizophr Bull.* 2018;44(1):168–181.
69. Giraldo-Chica M, Woodward ND. Review of thalamocortical resting-state fMRI studies in schizophrenia. *Schizophr Res.* 2017;180:58–63.
70. Gratton C, Laumann TO, Nielsen AN, et al. Functional brain networks are dominated by stable group and individual factors, not cognitive or daily variation. *Neuron.* 2018;98(2):439–452.e5.
71. McCabe C, Mishor Z. Antidepressant medications reduce subcortical-cortical resting-state functional connectivity in healthy volunteers. *Neuroimage.* 2011;57(4):1317–1323.
72. Wang Y, Tang W, Fan X, et al. Resting-state functional connectivity changes within the default mode network and the salience network after antipsychotic treatment in early-phase schizophrenia. *Neuropsychiatr Dis Treat.* 2017;13:397–406.
73. Martin-Brevet S, Rodríguez-Herreros B, Nielsen JA, et al. Quantifying the effects of 16p11.2 copy number variants on brain structure: A multisite genetic-first study. *Biol Psychiatry.* 2018;84(4):253–264.
74. Bai D, Yip BHK, Windham GC, et al. Association of genetic and environmental factors with autism in a 5-country cohort. *JAMA Psychiatry.* 2019;76(10):1035.
75. Hilker R, Helenius D, Fagerlund B, et al. Heritability of schizophrenia and schizophrenia spectrum based on the Nationwide Danish Twin Register. *Biol Psychiatry.* 2018;83(6):492–498.
76. Taylor MJ, Rosenqvist MA, Larsson H, et al. Etiology of autism spectrum disorders and autistic traits over time. *JAMA Psychiatry.* 2020;77(9):936.
77. Morris TT, Davies NM, Hemani G, Smith GD. Population phenomena inflate genetic associations of complex social traits. *Sci Adv.* 2020;6(16):eaay0328.
78. Gaugler T, Klei L, Sanders SJ, et al. Most genetic risk for autism resides with common variation. *Nat Genet.* 2014;46(8):881–885.
79. Iossifov I, Ronemus M, Levy D, et al. De novo gene disruptions in children on the autistic spectrum. *Neuron.* 2012;74(2):285–299.
80. Pinto D, Delaby E, Merico D, et al. Convergence of genes and cellular pathways dysregulated in autism spectrum disorders. *Am J Hum Genet.* 2014;94(5):677–694.
81. Moreno-De-Luca D, Sanders SJ, Willsey AJ, et al. Using large clinical data sets to infer pathogenicity for rare copy number variants in autism cohorts. *Mol Psychiatry.* 2013;18(10):1090–1095.
82. Douard E, Zeribi A, Schramm C, et al. Effect sizes of deletions and duplications on autism risk across the genome. *Am J Psychiatry.* 2021;178(1):87–98.
83. Sanders SJ, Murtha MT, Gupta AR, et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. *Nature.* 2012;485(7397):237–241.
84. Coe BP, Stessman HAF, Sulovari A, et al. Neurodevelopmental disease genes implicated by de novo mutation and copy number variation morbidity. *Nat Genet.* 2019;51(1):106–116.
85. Satterstrom FK, Kosmicki JA, Wang J, et al.; iPSYCH-Broad Consortium. Large-scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism. *Cell.* 2020;180(3):568–584.e23.
86. Howrigan DP, Rose SA, Samocha KE, et al. Exome sequencing in schizophrenia-affected parent-offspring trios reveals risk conferred by protein-coding de novo mutations. *Nat Neurosci.* 2020;23(2):185–193.
87. Farrell MS, Werge T, Sklar P, et al. Evaluating historical candidate genes for schizophrenia. *Mol Psychiatry.* 2015;20(5):555–562.
88. Fromer M, Pocklington AJ, Kavanagh DH, et al. De novo mutations in schizophrenia implicate synaptic networks. *Nature.* 2014;506(7487):179–184.
89. Singh T, Kurki MI, Curtis D, et al.; Swedish Schizophrenia Study. Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders. *Nat Neurosci.* 2016;19(4):571–577.
90. Takata A, Xu B, Ionita-Laza I, Roos JL, Gogos JA, Karayiorgou M. Loss-of-function variants in schizophrenia risk and SETD1A as a candidate susceptibility gene. *Neuron.* 2014;82(4):773–780.
91. Walsh T, McClellan JM, McCarthy SE, et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. *Science.* 2008;320(5875):539–543.
92. International Schizophrenia Consortium. Rare chromosomal deletions and duplications increase risk of schizophrenia. *Nature.* 2008;455:237–241.
93. Nishino J, Ochi H, Kochi Y, Tsunoda T, Matsui S. Sample size for successful genome-wide association study of major depressive disorder. *Front Genet.* 2018;9:227.
94. Downar J, Blumberger DM, Daskalakis ZJ. The neural crossroads of psychiatric illness: An emerging target for brain stimulation. *Trends Cogn Sci.* 2016;20(2):107–120.
95. Baribeau DA, Dupuis A, Paton TA, et al. Structural neuroimaging correlates of social deficits are similar in autism spectrum disorder and attention-deficit/hyperactivity disorder: Analysis from the POND Network. *Transl Psychiatry.* 2019;9(1):72.
96. Meda SA, Ruaño G, Windemuth A, et al. Multivariate analysis reveals genetic associations of the resting default mode network in psychotic bipolar disorder and schizophrenia. *Proc Natl Acad Sci U S A.* 2014;111(19):E2066–E2075.
97. Ongür D, Lundy M, Greenhouse I, et al. Default mode network abnormalities in bipolar disorder and schizophrenia. *Psychiatry Res.* 2010;183(1):59–68.
98. Huntenburg JM, Bazin P-L, Margulies DS. Large-scale gradients in human cortical organization. *Trends Cogn Sci.* 2018;22(1):21–31.
99. Brainstorm Consortium. Analysis of shared heritability in common disorders of the brain. *Science.* 2018;360(6395):eaap8757.
100. Cross-Disorder Group of the Psychiatric Genomics Consortium, Lee SH, Ripke S, et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. *Nat Genet.* 2013;45(9):984–994.
101. Marshall M. The hidden links between mental disorders. *Nature.* 2020;581(7806):19–21.

102. Kushima I, Aleksic B, Nakatochi M, et al. Comparative analyses of copy-number variation in autism spectrum disorder and schizophrenia reveal etiological overlap and biological insights. *Cell Rep*. 2018;24(11):2838–2856.
103. Gandal MJ, Haney JR, Parikshak NN, et al.; CommonMind Consortium. Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap. *Science*. 2018; 359(6376):693–697.
104. Kearney HM, Thorland EC, Brown KK, Quintero-Rivera F, South ST; Working Group of the American College of Medical Genetics Laboratory Quality Assurance Committee. American College of Medical Genetics standards and guidelines for interpretation and reporting of postnatal constitutional copy number variants. *Genet Med*. 2011;13(7):680–685.
105. Weiss LA, Shen Y, Korn JM, et al.; Autism Consortium. Association between microdeletion and microduplication at 16p11.2 and autism. *N Engl J Med*. 2008;358(7):667–675.
106. Niarchou M, Chawner SJRA, Doherty JL, et al. Psychiatric disorders in children with 16p11.2 deletion and duplication. *Transl Psychiatry*. 2019;9(1):8.
107. D'Angelo D, Lebon S, Chen Q, et al.; for the Cardiff University Experiences of Children With Copy Number Variants (ECHO) Study, the 16p11.2 European Consortium, and the Simons Variation in Individuals Project (VIP) Consortium. Defining the effect of the 16p11.2 duplication on cognition, behavior, and medical comorbidities. *JAMA Psychiatry*. 2016;73(1):20–30.
108. Moreno-De-Luca A, Evans DW, Boomer KB, et al. The role of parental cognitive, behavioral, and motor profiles in clinical variability in individuals with chromosome 16p11.2 deletions. *JAMA Psychiatry*. 2015;72(2):119–126.
109. Hippolyte L, Maillard AM, Rodriguez-Herreros B, et al.; 16p11.2 European Consortium, Simons Variation in Individuals Project Consortium. The number of genomic copies at the 16p11.2 locus modulates language, verbal memory, and inhibition. *Biol Psychiatry*. 2016;80(2):129–139.
110. Jacquemont S, Raymond A, Zufferey F, et al. Mirror extreme BMI phenotypes associated with gene dosage at the chromosome 16p11.2 locus. *Nature*. 2011;478(7367):97–102.
111. Zufferey F, Sherr EH, Beckmann ND, et al.; 16p11.2 European Consortium. A 600 kb deletion syndrome at 16p11.2 leads to energy imbalance and neuropsychiatric disorders. *J Med Genet*. 2012;49(10):660–668.
112. Maillard AM, Ruef A, Pizzagalli F, et al.; 16p11.2 European Consortium. The 16p11.2 locus modulates brain structures common to autism, schizophrenia and obesity. *Mol Psychiatry*. 2015;20(1):140–147.
113. Bertero A, Liska A, Pagani M, et al. Autism-associated 16p11.2 microdeletion impairs prefrontal functional connectivity in mouse and human. *Brain*. 2018;141(7):2055–2065.
114. Jonas RK, Montojo CA, Bearden CE. The 22q11.2 deletion syndrome as a window into complex neuropsychiatric disorders over the lifespan. *Biol Psychiatry*. 2014;75(5):351–360.
115. Karayiorgou M, Morris MA, Morrow B, et al. Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11. *Proc Natl Acad Sci U S A*. 1995;92(17):7612–7616.
116. Philip N, Bassett A. Cognitive, behavioural and psychiatric phenotype in 22q11.2 deletion syndrome. *Behav Genet*. 2011; 41(3):403–412.
117. Schneider M, Debbané M, Bassett AS, et al.; for the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: Results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. *Am J Psychiatry*. 2014;171(6):627–639.
118. Rees E, Kirov G, Sanders A, et al.; Wellcome Trust Case Control Consortium. Evidence that duplications of 22q11.2 protect against schizophrenia. *Mol Psychiatry*. 2014;19(1):37–40.
119. Olsen L, Sparsø T, Weinsheimer SM, et al. Prevalence of rearrangements in the 22q11.2 region and population-based risk of neuropsychiatric and developmental disorders in a Danish population: A case-cohort study. *Lancet Psychiatry*. 2018;5(7):573–580.
120. Sun D, Ching CRK, Lin A, et al. Large-scale mapping of cortical alterations in 22q11.2 deletion syndrome: Convergence with idiopathic psychosis and effects of deletion size. *Mol Psychiatry*. 2020;25(8):1822–1834.
121. Ching CRK, Gutman BA, Sun D, et al. Mapping subcortical brain alterations in 22q11.2 deletion syndrome: Effects of deletion size and convergence with idiopathic neuropsychiatric illness. *Am J Psychiatry*. 2020;177(7):589–600.
122. Lin A, Ching CRK, Vajdi A, et al. Mapping 22q11.2 gene dosage effects on brain morphometry. *J Neurosci*. 2017;37(26):6183–6199.
123. Mattiaccio LM, Coman IL, Thompson CA, Fremont WP, Antshel KM, Kates WR. Frontal dysconnectivity in 22q11.2 deletion syndrome: An atlas-based functional connectivity analysis. *Behav Brain Funct*. 2018;14(1):2.
124. Schleifer C, Lin A, Kushan L, et al. Dissociable disruptions in thalamic and hippocampal resting-state functional connectivity in youth with 22q11.2 deletions. *J Neurosci*. 2019;39(7):1301–1319.
125. Escamilla CO, Filonova I, Walker AK, et al. Kctd13 deletion reduces synaptic transmission via increased RhoA. *Nature*. 2017;551(7679):227–231.
126. Richter M, Murtaza N, Scharrenberg R, et al. Altered TAOX2 activity causes autism-related neurodevelopmental and cognitive abnormalities through RhoA signaling. *Mol Psychiatry*. 2019;24(9):1329–1350.
127. Golzio C, Willer J, Talkowski ME, et al. KCTD13 is a major driver of mirrored neuroanatomical phenotypes of the 16p11.2 copy number variant. *Nature*. 2012;485(7398):363–367.
128. Hiroi N, Takahashi T, Hishimoto A, Izumi T, Boku S, Hiramoto T. Copy number variation at 22q11.2: From rare variants to common mechanisms of developmental neuropsychiatric disorders. *Mol Psychiatry*. 2013;18(11):1153–1165.
129. Motahari Z, Moody SA, Maynard TM, LaMantia A-S. In the lineup: Deleted genes associated with DiGeorge/22q11.2 deletion syndrome: Are they all suspects? *J Neurodev Disord*. 2019;11(1):7.
130. Ellegood J, Anagnostou E, Babineau BA, et al. Clustering autism: Using neuroanatomical differences in 26 mouse models to gain insight into the heterogeneity. *Mol Psychiatry*. 2015;20(1):118–125.
131. Warland A, Kendall KM, Rees E, Kirov G, Caseras X. Schizophrenia-associated genomic copy number variants and subcortical brain volumes in the UK Biobank. *Mol Psychiatry*. 2020;25(4):854–862.
132. Huguet G, Schramm C, Douard E, et al. Genome-wide analysis of gene dosage in 24,092 individuals estimates that 10,000 genes modulate cognitive ability. *Mol Psychiatry*. Published online 7 January 2021. doi:10.1038/s41380-020-00985-z
133. Huguet G, Schramm C, Douard E, et al.; for the IMAGEN Consortium. Measuring and estimating the effect sizes of copy number variants on general intelligence in community-based samples. *JAMA Psychiatry*. 2018;75(5):447.
134. Lek M, Karczewski KJ, Minikel EV, et al.; Exome Aggregation Consortium. Analysis of protein-coding genetic variation in 60,706 humans. *Nature*. 2016;536(7616):285–291.
135. Drakesmith M, Parker GD, Smith J, et al. Genetic risk for schizophrenia and developmental delay is associated with shape and microstructure of midline white-matter structures. *Transl Psychiatry*. 2019;9(1):102.
136. Shen L, Thompson PM. Brain imaging genomics: Integrated analysis and machine learning. *Proc IEEE*. 2020;135:108(1):125–162.

137. Neilson E, Shen X, Cox SR, et al. Impact of polygenic risk for schizophrenia on cortical structure in UK biobank. *Biol Psychiatry*. 2019;86(7):536–544.
138. Reus LM, Shen X, Gibson J, et al. Association of polygenic risk for major psychiatric illness with subcortical volumes and white matter integrity in UK Biobank. *Sci Rep*. 2017;7:42140.
139. Van der Auwera S, Wittfeld K, Homuth G, Teumer A, Hegenscheid K, Grabe HJ. No association between polygenic risk for schizophrenia and brain volume in the general population. *Biol Psychiatry*. 2015;78(11):e41–e42.
140. Alnæs D, Kaufmann T, van der Meer D, et al.; Karolinska Schizophrenia Project Consortium. Brain heterogeneity in schizophrenia and its association with polygenic risk. *JAMA Psychiatry*. 2019;76(7):739–748.
141. Alemany S, Jansen PR, Muetzel RL, et al. Common polygenic variations for psychiatric disorders and cognition in relation to brain morphology in the general pediatric population. *J Am Acad Child Adolesc Psychiatry*. 2019;58(6):600–607.
142. Grotzinger AD, Rhemtulla M, de Vlaming R, et al. Genomic structural equation modelling provides insights into the multivariate genetic architecture of complex traits. *Nat Hum Behav*. 2019;3(5):513–525.
143. Burt JB, Demirtaş M, Eckner WJ, et al. Hierarchy of transcriptional specialization across human cortex captured by structural neuroimaging topography. *Nat Neurosci*. 2018;21(9):1251–1259.
144. Müller E, Munn B, Hearne LJ, et al. Core and matrix thalamic sub-populations relate to spatio-temporal cortical connectivity gradients. *Neuroimage*. 2020;222:117224.
145. Lewis CM, Vassos E. Polygenic risk scores: From research tools to clinical instruments. *Genome Med*. 2020;12(1):44.
146. Hawrylycz M, Miller JA, Menon V, et al. Canonical genetic signatures of the adult human brain. *Nat Neurosci*. 2015;18(12):1832–1844.
147. Seidlitz J, Nadig A, Liu S, et al. Transcriptomic and cellular decoding of regional brain vulnerability to neurogenetic disorders. *Nat Commun*. 2020;11(1):3358.
148. Writing Committee for the Attention-Deficit/Hyperactivity Disorder; Autism Spectrum Disorder; Bipolar Disorder; Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders. *JAMA Psychiatry*. 2021;78(1):47–63.
149. Whitaker KJ, Vértes PE, Romero-Garcia R, et al.; NSPN Consortium. Adolescence is associated with genomically patterned consolidation of the hubs of the human brain connectome. *Proc Natl Acad Sci U S A*. 2016;113(32):9105–9110.
150. Kebets V, Holmes AJ, Orban C, et al. Somatosensory-motor dysconnectivity spans multiple transdiagnostic dimensions of psychopathology. *Biol Psychiatry*. 2019;86(10):779–791.
151. Reardon PK, Seidlitz J, Vandekar S, et al. Normative brain size variation and brain shape diversity in humans. *Science*. 2018;360(6394):1222–1227.
152. van den Heuvel MP, Scholtens LH, de Lange SC, et al. Evolutionary modifications in human brain connectivity associated with schizophrenia. *Brain*. 2019;142(12):3991–4002.
153. Esteban O, Markiewicz CJ, Blair RW, et al. fMRIPrep: A robust preprocessing pipeline for functional MRI. *Nat Methods*. 2019;16(1):111–116.
154. Pedregosa F, Varoquaux G, Gramfort A. Scikit-learn: Machine learning in Python. *J Mach Learn Res*. 2011;12(85):2825–2830.
155. Crawford KL, Neu SC, Toga AW. The image and data archive at the laboratory of neuro imaging. *Neuroimage*. 2016;124(Pt B):1080–1083.
156. Das S, Zijdenbos A, Vins D, Harlap J, Evans A. LORIS: A web-based data management system for multi-center studies. *Front Neuroinform*. 2011;5:37.
157. Gorgolewski KJ, Auer T, Calhoun VD, et al. The brain imaging data structure, a format for organizing and describing outputs of neuroimaging experiments. *Sci Data*. 2016;3:160044.
158. Moreau CA, Jean-Louis M, Blair R, et al. The genetics-BIDS extension: Easing the search for genetic data associated with human brain imaging. *Gigascience*. 2020;9(10):9.
159. Sullivan PF, Agrawal A, Bulik CM, et al.; for the Psychiatric Genomics Consortium. Psychiatric genomics: An update and an agenda. *Am J Psychiatry*. 2018;175(1):15–27.
160. Thompson PM, Stein JL, Medland SE, et al.; Alzheimer's Disease Neuroimaging Initiative, EPIGEN Consortium, IMAGEN Consortium, Saguenay Youth Study (SYS) Group. The ENIGMA Consortium: Large-scale collaborative analyses of neuroimaging and genetic data. *Brain Imaging Behav*. 2014;8(2):153–182.
161. Sudlow C, Gallacher J, Allen N, et al. UK biobank: An open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med*. 2015;12(3):e1001779.
162. McPherson JD, Marra M, Hillier L, et al. A physical map of the human genome. *Nature*. 2001;409:934–941.
163. Weiner MW, Aisen PS, Jack CR Jr, et al.; Alzheimer's Disease Neuroimaging Initiative. The Alzheimer's disease neuroimaging initiative: progress report and future plans. *Alzheimers Dement*. 2010;6(3):202–211.e7.
164. 1000 Genomes Project Consortium, Abecasis GR, Altshuler D, et al. A map of human genome variation from population-scale sequencing. *Nature*. 2010;467(7319):1061–1073.
165. HD-200 Consortium. The ADHD-200 Consortium: A model to advance the translational potential of neuroimaging in clinical neuroscience. *Front Syst Neurosci*. 2012;6:62.
166. Poldrack RA, Barch DM, Mitchell JP, et al. Toward open sharing of task-based fMRI data: The OpenfMRI project. *Front Neuroinform*. 2013;7:12.
167. Amunts K, Ebell C, Muller J, Telefont M, Knoll A, Lippert T. The human brain project: Creating a European research infrastructure to decode the human brain. *Neuron*. 2016;92(3):574–581.
168. Gorgolewski KJ, Varoquaux G, Rivera G, et al. NeuroVault.org: A web-based repository for collecting and sharing unthresholded statistical maps of the human brain. *Front Neuroinform*. 2015;9:8.
169. Glasser MF, Smith SM, Marcus DS, et al. The Human Connectome Project's neuroimaging approach. *Nat Neurosci*. 2016;19(9):1175–1187.
170. Jernigan TL, Brown TT, Hagler DJ Jr, et al.; Pediatric Imaging, Neurocognition and Genetics Study. The Pediatric Imaging, Neurocognition, and Genetics (PING) Data Repository. *Neuroimage*. 2016;124(Pt B):1149–1154.
171. Kogan A, Alpert K, Ambite JL, Marcus DS, Wang L. Northwestern University schizophrenia data sharing for SchizConnect: A longitudinal dataset for large-scale integration. *Neuroimage*. 2016;124(Pt B):1196–1201.
172. Loth E, Charman T, Mason L, et al. The EU-AIMS Longitudinal European Autism Project (LEAP): Design and methodologies to identify and validate stratification biomarkers for autism spectrum disorders. *Mol Autism*. 2017;8:24.
173. Casey BJ, Cannonier T, Conley MI, et al.; ABCD Imaging Acquisition Workgroup. The Adolescent Brain Cognitive Development (ABCD) study: Imaging acquisition across 21 sites. *Dev Cogn Neurosci*. 2018;32:43–54.